Lucid Diagnostics
Lucid Diagnostics Partners With Front Line Mobile to Promote Esophageal Cancer Test
Working with the first responder medical care provider, Lucid is planning high-volume testing events among firefighters and other frontline workers with elevated risk.
Lucid Diagnostics' Esophageal Precancer Test Sales Spike in Q2
The firm's revenues, all from the EsoGuard DNA screening test, increased to $976,000 in Q2 compared to $159,000 in the same quarter last year.
In Brief This Week: Genprex, Veracyte, C2i Genomics, Arvinas, Pfizer, AstraZeneca, Sophia Genetics
News items for the week of Feb. 5, 2024.